AI projects in rare diseases can start with limited scope and then take different directions and start to evolve into longer programmes of work over time
We present 4 case studies demonstrating how the expectations and also objectives can change over time to develop more impact for patients
We will also show top-line results for each of these case studies
Q&A will be taken at the Volv booth (513)
Leon van Wouwe,Clinical Innovation Director, volv global
Day 1 - World Orphan Drug Congress USA 2024 11:45, AI & Digital Health
How you can deliver consequential projects using AI in multi-year deployments for patient
AI projects in rare diseases can start with limited scope and then take different directions and start to evolve into longer programmes of work over time
We present 4 case studies demonstrating how the expectations and also objectives can change over time to develop more impact for patients
We will also show top-line results for each of these case studies
Q&A will be taken at the Volv booth (513)
Leon van Wouwe,Clinical Innovation Director, volv global